Stocks & Bonds

COT Report: Traders Lighten Up Into Big Economic Data Week

The following is a recap of The COT Report (Commitment Of Traders) released by the CFTC (Commodity Futures Trading Commission) looking at futures positions of non-commercial holdings as of May 19, 2015. Note that the change is week-over-week. 10-Year Treasury Note: The April FOMC minutes for all intents and purposes put a nail in the coffin of June rate-hike odds.  At the March meeting, “several” Fed officials thought they should

Top Trading Links: Don’t Fall For The Market Lull-aby

The overall market was quite bland into the long holiday weekend. Undoubtedly, it’s been a stock picker’s market. Given the recent sentiment surveys, it’s safe to say many managers followed the chaser’s playbook. But don’t let the the holiday induced stock market lull you to sleep. There were lots of great reads around the financial web, so let’s dig in to this week’s “Top Trading Links”.   Market Insights The

Intel Corp (INTC) Stock Update: Base Building

When I last looked at Intel Corp. (INTC), the stock had just put out strong earnings and was attempting to bounce after a 3 month decline of around 25 percent. At that time, the setup and earnings report looked good but we were waiting to see if the “big money” felt the same. As well, the stock price (at that time) was below it’s 50 day moving average and downtrend. Here’s an

Apple Inc. (AAPL) Chart Update: Price Pattern Still In Play?

Apple’s stock has spent the past few months consolidating some big gains. And the consolidation range has been wide and tradable for those that are more active. But as Apple Inc. (AAPL) nears its all-time highs again, investors are busy debating whether slowing momentum will lead to a top. That’s a valid question and long-term investors will need to watch price indicators closely to determine exposure. This past February, I

3 Bond Market ETFs Showing Surprising Strength

The weakness in the bond market this year has been primarily centered on Treasury and investment grade corporate debt, which has the highest sensitivity to interest rates. This of course has filtered down to indexes that are heavily overweight quality U.S. bonds. As an example, the iShares Core U.S. Aggregate Bond ETF (AGG) is essentially flat so far this year and erased one-third of its gains in the last 12-months

S&P 500 Hits Major Fibonacci Milestone; Market Looks Tired

Technicians and those technically inclined have waited with abated breath to see if the S&P 500 large cap index would hit 2138.  That price marks the 161.8 Fibonacci extension of the October ’07 to March ’09 decline. For Fibonacci followers, this is an important sequence. That level was hit yesterday. Well, almost. Post-FOMC minutes, the intra-day high yesterday was 2134.72.  Now that the Fib target has been hit, what next?

Inside The IPO ETF: Know What You Own

Several ETFs provide valuable information about how securities, sectors, or indexes are faring. Investors often turn to them because they are tradable and provide decent coverage industries and assets. That said, it’s also important to look at the makeup of each ETF. Digging through the holdings and structures can provide us with plenty of information. Today, I want to take a look at the Renaissance IPO ETF (IPO), which tracks IPO’s (Initial

S&P 500 Chart: Price Compresses As Traders Await Next Move

As many momentum, directional and trend traders will attest, the past several months have been pure chop. Despite the new all-time-highs for the S&P 500 Index (SPX), the move higher has been a series of stutter steps. Checking in on the chart of the SPDR S&P 500 ETF (SPY), we can see a clear pattern of smaller pullbacks and bounces since the February rebound. SPY has hovered in a neutral

Twitter (TWTR) Options Trading Idea: A Cash Secured Put

Not much has changed fundamentally since we last discussed Twitter stock (TWTR). That was Monday last week. Except President Obama has his own Twitter account now. In the past week, Twitter earnings estimates for the second and third quarters have remained unchanged at five and six cents respectively, as have for 2015 and 2016, at $0.34 and $0.67, in that order. The stock is still trying to digest the earnings-induced

Kite Pharma (KITE): Careful Catching This Falling Knife

I don’t pretend for a second to understand the science behind Kite Pharma (KITE) business, but I do know several smart biotech investors and analysts who are pretty convinced that its technology will prove to be the real deal at least as it pertains to blood cancers. I have never been involved in KITE, but I’ve been watching it for some time to see if/when it may offer a decent entry